Moore, N.F ;
Azarova, A.M ;
Bhatnagar, N...
Moore, N.F, Azarova, A.M, Bhatnagar, N, Ross, K.N, Drake, L.E, Frumm, S, Liu, Q.S, Christie, A.L, Sanda, T, Chesler, L, Kung, A.L, Gray, N.S, Stegmaier, K, George, R.E (2014). Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget 5 (18) : 8737-8749. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.2372.
,
2014